Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDGLNASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDGLMadrigal Pharmaceuticals$294.64-1.6%$322.72$200.63▼$377.46$6.54B-0.91385,454 shs305,937 shsVKTXViking Therapeutics$27.61-0.9%$26.19$18.92▼$81.73$3.10B0.754.11 million shs1.73 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDGLMadrigal Pharmaceuticals+0.25%-8.58%-1.06%-9.96%+44.00%VKTXViking Therapeutics+1.00%-2.66%+39.39%-14.47%-65.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMDGLMadrigal Pharmaceuticals4.5989 of 5 stars4.50.00.04.63.44.20.6VKTXViking Therapeutics4.5624 of 5 stars4.52.00.04.72.93.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$416.3341.30% UpsideVKTXViking Therapeutics 3.00Buy$87.15215.66% UpsideCurrent Analyst Ratings BreakdownLatest VKTX and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$443.00 ➝ $443.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.00(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDGLMadrigal Pharmaceuticals$317.38M20.61N/AN/A$20.53 per share14.35VKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDGLMadrigal Pharmaceuticals-$373.63M-$18.05N/AN/AN/AN/A-71.78%-53.25%N/AVKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)Latest VKTX and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A2/26/2025Q4 2024MDGLMadrigal Pharmaceuticals-$4.32-$2.71+$1.61-$2.71$97.81 million$103.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDGLMadrigal Pharmaceuticals0.155.985.93VKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDGLMadrigal Pharmaceuticals98.50%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipMDGLMadrigal Pharmaceuticals22.80%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDGLMadrigal Pharmaceuticals9022.20 million16.84 millionOptionableVKTXViking Therapeutics20112.31 million106.20 millionOptionableVKTX and MDGL HeadlinesRecent News About These CompaniesBoone Capital Management LLC Boosts Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 8 at 6:30 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Position Lifted by Braidwell LPMay 8 at 6:29 AM | marketbeat.comAptus Capital Advisors LLC Purchases 10,564 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)May 8 at 4:57 AM | marketbeat.comCantor Fitzgerald L. P. Takes $380,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 7 at 6:53 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Bamco Inc. NYMay 7 at 5:58 AM | marketbeat.comAQR Capital Management LLC Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 6 at 4:47 AM | marketbeat.comWhy Viking Therapeutics Stock Surged Nearly 20% Higher in AprilMay 6 at 4:33 AM | fool.comApis Capital Advisors LLC Has $3.86 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 5, 2025 | marketbeat.com5AM Venture Management LLC Has $7.63 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 4, 2025 | marketbeat.com683 Capital Management LLC Lowers Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 4, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by MML Investors Services LLCMay 4, 2025 | marketbeat.comResearch Analysts Set Expectations for VKTX FY2025 EarningsMay 3, 2025 | marketbeat.comViking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025May 3, 2025 | finance.yahoo.comWhy Viking Therapeutics Stock Was Victorious This WeekMay 2, 2025 | fool.comWhy Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped FridayMay 2, 2025 | fool.comViking Therapeutics (NASDAQ:VKTX) Raised to "Strong-Buy" at Cantor FitzgeraldMay 2, 2025 | marketbeat.comWhere Will Viking Therapeutics Be in 3 Years?May 2, 2025 | fool.comTraders Purchase Large Volume of Viking Therapeutics Call Options (NASDAQ:VKTX)May 2, 2025 | marketbeat.comBrokers Offer Predictions for VKTX FY2025 EarningsMay 2, 2025 | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Shares Gap Up - What's Next?May 1, 2025 | marketbeat.com1 Beaten-Down Stock to Buy and Hold for 10 YearsMay 1, 2025 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsViking Therapeutics Stock May Struggle After As-Expected ReportBy Chris Markoch | April 25, 2025View Viking Therapeutics Stock May Struggle After As-Expected ReportVKTX and MDGL Company DescriptionsMadrigal Pharmaceuticals NASDAQ:MDGL$294.64 -4.93 (-1.65%) As of 04:00 PM EasternMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Viking Therapeutics NASDAQ:VKTX$27.61 -0.24 (-0.86%) As of 03:58 PM EasternViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Why Flutter Entertainment May Be a Resilient Sports Betting Stock OXY Stock Rebound Begins Following Solid Earnings Beat Is Energy Transfer Undervalued or a Value Trap? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
